Navigation Links
Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
Date:5/20/2011

MOUNTAIN VIEW, Calif., May 20, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the upcoming European Congress on Obesity meeting to be held May 25 to May 28, 2011, at the ICEC Lutfi Kirdar Convention & Exhibition Center in Istanbul, Turkey.  The details of the presentations are as follows:Oral presentation:Friday, May 27 – Novel Drugs Session, Presentation time 17:15-17:30 (local time)Authors:  

Stephan Rossner, MD, PhD; Craig A. Peterson, MS; Barbara Troupin, MD, MBATitle:  

CARDIOMETABOLIC RISK REDUCTION IS DIRECTLY RELATED TO MAGNITUDE OF WEIGHT LOSS WITH LOW DOSE, CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) [T5:RS4.4]Poster presentations:Thursday, May 26– Hot Topic Poster Session, Presentation time 13:00-15:00 (local time)Authors:  

George A. Bray, MD; Louis J. Aronne, MD; Alok K. Gupta, MD; Wesley W. Day, PhD; Barbara Troupin, MD, MBATitle:  

EFFICACY AND TOLERABILITY OF TOPIRAMATE ALONE AND IN COMBINATION WITH PHENTERMINE [HTP.025]Friday, May 27– Poster Session, Presentation time 13:00-15:00 (local time)Authors:  

W. Timothy Garvey, MD; Craig A. Peterson, MS; Barbara Troupin, MD, MBATitle:  

WEIGHT LOSS WITH LOW-DOSE, CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE THERAPY IMPROVES GLYCAEMIC STATUS AND PREVENTS PROGRESSION TO TYPE 2 DIABETES MELLITUS [T5:P.102]Authors:  

W. Timothy Garvey, MD; Wesley W. Day, PhD, Charles H. Bowden, MDTitle:  

LONG-TERM TREATMENT WITH CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE DEMONSTRATES SUSTAINED WEIGHT LOSS OVER 108 WEEKS [T5:P.103]All posters will be displayed in the Exhibition Hall from the afternoon of May 25th until the morning of May 28th.

About QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has completed its phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect" and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  VIVUS does not undertake an obligation to update or revise any forward-looking statements.  Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.  

CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian Korb Chief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years clinical ... and biotechnology industries. His last role was at Mologen ... of the Executive Board. Previously Dr. Zurlo held various ...
(Date:4/28/2016)... Calif. , April 28, 2016  Marking ... widely accessible breast and ovarian cancer risk test, ... panel analyzing 30 genes that highly impact the ... women. Available today, the Color Test analyzes hereditary ... prostate, stomach, and uterine cancers. The Color Test ...
(Date:4/28/2016)... 2016 Dr. Vivek Ahuja , ... Ste phen Schmidt ... provider of cloud-based software solutions for life sciences, today announced key ... a wealth of insight to a growing business.  This will bolster ... George Phillips joined ArisGlobal in the position of Vice ...
Breaking Medicine Technology:
(Date:4/29/2016)... FL (PRWEB) , ... April 30, 2016 , ... ... and engineer of patented products, announces the Pick Up Springboard, an automotive invention ... and Light Truck Manufacturing industry is worth $162 billion," says Scott Cooper, CEO ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... Sterling, VA (PRWEB) , ... April 29, 2016 ... ... Americans with student loans more flexibility in repaying their loans, more information about ... at a time when total outstanding student loan debt, including federal and private ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the dentists ... dentistry is a fast-growing field as more patients are discovering the many different ways ... about the options currently available to them and which ones might work for their ...
Breaking Medicine News(10 mins):